HepQuant Appoints Investment Banking Industry Veteran Chris Jensen to Corporate Advisory Board

DENVER–(BUSINESS WIRE)–HepQuant, LLC, a Denver, Colo.-based company that owns a unique, patented and patent-pending technology to assess the liver in patients with chronic liver disease, announced today that Former JP Morgan investment banker Chris Jensen has been named to HepQuant’s Business Advisory Council.

Previously, Mr. Jensen served as a senior executive for Chase Commercial Banking, supporting JP Morgan’s Greater West segment in the development of commercial and investment banking businesses. He has also served on the board of directors for the Metro Denver Chamber of Commerce, the Downtown Denver Partnership and the Colorado Bankers Association.

“HepQuant is actively planning its capital requirements and is fortunate to have Chris Jensen, with his 35 years of investment banking experience, supporting our efforts,” said Dr. Gregory T. Everson, CEO and Chief Medical Officer at HepQuant.

As a regional manager at Chase Commercial Banking in Colorado from early 2016 to mid-2019, he led banking teams serving middle market businesses in the state. Prior to this role, he spent nearly three decades as a managing director of investment banking at JP Morgan for a range of clients in New York, Tokyo and Denver, supporting them with advisory, capital raising and mergers and acquisitions. Its clients have competed in the healthcare, pharmaceutical, technology and fintech industries.

“I have known Greg Everson and HepQuant President Randy Dietrich for many years and have seen their remarkable progress,” Mr. Jensen said. “I appreciate HepQuant’s potential to revolutionize the field of liver diagnostics and look forward to supporting this team and its goals.”

A finance graduate from the University of Utah, Mr. Jensen received his MBA in finance and accounting from the UCLA Anderson School of Management.

About HepQuant

Based in Denver, Colorado, HepQuant, LLC is a private diagnostics company. HepQuant products are investigational combination drugs and in vitro diagnostic devices and have not yet been evaluated or reviewed by the United States Food and Drug Administration (FDA) for commercial sale. They are currently available for experimental use through the FDA’s guidelines for Investigational Device Exemptions (IDEs). For more information, visit www.hepquant.com.

About the author